Shimony, S., Stahl, M. & Stone, R. M. Acute myeloid leukemia: 2023 replace on analysis, risk-stratification, and administration. Am. J. Hematol. 98, 502–526 (2023).
Appelbaum, F. R. et al. Age and acute myeloid leukemia. Blood 107, 3481–3485 (2006).
Bhansali, R. S., Pratz, Ok. W. & Lai, C. Current advances in focused therapies in acute myeloid leukemia. J. Hematol. Oncol. 16, 29 (2023).
DiNardo, C. D. et al. Venetoclax mixed with decitabine or azacitidine in treatment-naive, aged sufferers with acute myeloid leukemia. Blood 133, 7–17 (2019).
DiNardo, C. D. et al. Azacitidine and venetoclax in beforehand untreated acute myeloid leukemia. N. Engl. J. Med. 383, 617–629 (2020).
Tsherniak, A. et al. Defining a most cancers dependency map. Cell 170, 564–576 (2017).
Burger, J. A. Therapy of persistent lymphocytic leukemia. N. Engl. J. Med. 383, 460–473 (2020).
Jordan, V. C. & O’Malley, B. W. Selective estrogen-receptor modulators and antihormonal resistance in breast most cancers. J. Clin. Oncol. 25, 5815–5824 (2007).
Watson, P. A., Arora, V. Ok. & Sawyers, C. L. Rising mechanisms of resistance to androgen receptor inhibitors in prostate most cancers. Nat. Rev. Most cancers 15, 701–711 (2015).
Yu, A. L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324–1334 (2010).
Burger, J. A. et al. Lengthy-term efficacy and security of first-line ibrutinib remedy for sufferers with CLL/SLL: 5 years of follow-up from the part 3 RESONATE-2 research. Leukemia 34, 787–798 (2020).
Millis, S. Z., Ikeda, S., Reddy, S., Gatalica, Z. & Kurzrock, R. Panorama of phosphatidylinositol-3-kinase pathway alterations throughout 19 784 numerous stable tumors. JAMA Oncol. 2, 1565–1573 (2016).
Hirai, H. et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by normal chemotherapeutic brokers or molecular focused medicine in vitro and in vivo. Mol. Most cancers Ther. 9, 1956–1967 (2010).
Maira, S. M. et al. Identification and characterization of NVP-BKM120, an orally obtainable pan-class I PI3-kinase inhibitor. Mol. Most cancers Ther. 11, 317–328 (2012).
Maira, S. M. et al. Identification and characterization of NVP-BEZ235, a brand new orally obtainable twin phosphatidylinositol 3-kinase/mammalian goal of rapamycin inhibitor with potent in vivo antitumor exercise. Mol. Most cancers Ther. 7, 1851–1863 (2008).
Di Leo, A. et al. Buparlisib plus fulvestrant in postmenopausal ladies with hormone-receptor-positive, HER2-negative, superior breast most cancers progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, part 3 trial. Lancet Oncol. 19, 87–100 (2018).
Hopkins, B. D. et al. Suppression of insulin suggestions enhances the efficacy of PI3K inhibitors. Nature 560, 499–503 (2018).
Krop, I. E. et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, superior or metastatic breast most cancers (FERGI): a randomised, double-blind, placebo-controlled, part 2 trial. Lancet Oncol. 17, 811–821 (2016).
Furman, R. R. et al. Idelalisib and rituximab in relapsed persistent lymphocytic leukemia. N. Engl. J. Med. 370, 997–1007 (2014).
De Henau, O. et al. Overcoming resistance to checkpoint blockade remedy by focusing on PI3Kγ in myeloid cells. Nature 539, 443–447 (2016).
Foubert, P., Kaneda, M. M. & Varner, J. A. PI3Kγ prompts integrin α4 and promotes immune suppressive myeloid cell polarization throughout tumor development. Most cancers Immunol. Res. 5, 957–968 (2017).
Schmid, M. C. et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent level selling tumor irritation and development. Most cancers Cell 19, 715–727 (2011).
Kaneda, M. M. et al. PI3Kγ is a molecular change that controls immune suppression. Nature 539, 437–442 (2016).
Hong, D. S. et al. Eganelisib, a first-in-class PI3Kγ inhibitor, in sufferers with superior stable tumors: outcomes of the part 1/1b MARIO-1 trial. Clin. Most cancers Res. 29, 2210–2219 (2023).
Gu, H. et al. PI3Kγ maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood 143, 1965–1979 (2024).
Tyner, J. W. et al. Useful genomic panorama of acute myeloid leukaemia. Nature 562, 526–531 (2018).
van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies related to illness development and immunity. Cell 176, 1265–1281 (2019).
Ng, S. W. et al. A 17-gene stemness rating for fast dedication of threat in acute leukaemia. Nature 540, 433–437 (2016).
Most cancers Genome Atlas Analysis, N. et al. Genomic and epigenomic landscapes of grownup de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074, (2013).
Shymanets, A. et al. p87 and p101 subunits are distinct regulators figuring out class IB phosphoinositide 3-kinase (PI3K) specificity. J. Biol. Chem. 288, 31059–31068 (2013).
Stephens, L. R. et al. The Gβγ sensitivity of a PI3K relies upon a tightly related adaptor, p101. Cell 89, 105–114 (1997).
Horejsi, Z. et al. CK2 phospho-dependent binding of R2TP complicated to TEL2 is important for mTOR and SMG1 stability. Mol. Cell 39, 839–850 (2010).
Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor–mTOR complicated. Science 307, 1098–1101 (2005).
Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655–1657 (2002).
Pham, L. V. et al. Strategic therapeutic focusing on to beat venetoclax resistance in aggressive B-cell lymphomas. Clin. Most cancers Res. 24, 3967–3980 (2018).
Sathe, A. et al. Parallel PI3K, Akt and mTOR inhibition is required to regulate suggestions loops that restrict tumor remedy. PLoS ONE 13, e0190854 (2018).
Tavor, S. et al. CXCR4 regulates migration and improvement of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Most cancers Res. 64, 2817–2824 (2004).
Fields, T. A. & Casey, P. J. Signalling capabilities and biochemical properties of pertussis toxin-resistant G-proteins. Biochem. J. 321, 561–571 (1997).
Houslay, D. M. et al. Coincident indicators from GPCRs and receptor tyrosine kinases are uniquely transduced by PI3Kβ in myeloid cells. Sci. Sign. 9, ra82 (2016).
Bondeson, D. P. et al. Classes in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem. Biol. 25, 78–87 (2018).
Buhimschi, A. D. et al. Concentrating on the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase utilizing PROTAC-mediated degradation. Biochemistry 57, 3564–3575 (2018).
Douglass, E. F. Jr., Miller, C. J., Sparer, G., Shapiro, H. & Spiegel, D. A. A complete mathematical mannequin for three-body binding equilibria. J. Am. Chem. Soc. 135, 6092–6099 (2013).
Wurz, R. P. et al. Affinity and cooperativity modulate ternary complicated formation to drive focused protein degradation. Nat. Commun. 14, 4177 (2023).
Lu, J. et al. Hijacking the E3 ubiquitin ligase Cereblon to effectively goal BRD4. Chem. Biol. 22, 755–763 (2015).
Chua, C. C. et al. Chemotherapy and venetoclax in aged acute myeloid leukemia trial (CAVEAT): a part Ib dose-escalation research of venetoclax mixed with modified intensive chemotherapy. J. Clin. Oncol. 38, 3506–3517 (2020).
Rahmani, M. et al. Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Most cancers Res. 78, 3075–3086 (2018).
Lin, Ok. H. et al. Concentrating on MCL-1/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci. Rep. 6, 27696 (2016).
Evans, C. A. et al. Discovery of a selective phosphoinositide-3-kinase (PI3K)-γ inhibitor (IPI-549) as an immuno-oncology scientific candidate. ACS Med. Chem. Lett. 7, 862–867 (2016).
Gangadhara, G. et al. A category of extremely selective inhibitors bind to an energetic state of PI3Kγ. Nat. Chem. Biol. 15, 348–357 (2019).
Vanhaesebroeck, B., Ali, Ok., Bilancio, A., Geering, B. & Foukas, L. C. Signalling by PI3K isoforms: insights from gene-targeted mice. Developments Biochem. Sci. 30, 194–204 (2005).
Nürnberg, B. & Beer-Hammer, S.Operate, regulation and organic roles of PI3Kγ variants. Biomolecules 9, 427 (2019).
Perino, A., Ghigo, A., Scott, J. D. & Hirsch, E. Anchoring proteins as regulators of signaling pathways. Circ. Res. 111, 482–492 (2012).
Patrucco, E. et al. PI3Kγ modulates the cardiac response to persistent strain overload by distinct kinase-dependent and -independent results. Cell 118, 375–387 (2004).
Beretta, M., Bauer, M. & Hirsch, E. PI3K signaling within the pathogenesis of weight problems: the trigger and the remedy. Adv. Biol. Regul. 58, 1–15 (2015).
Damilano, F., Perino, A. & Hirsch, E. PI3K kinase and scaffold capabilities in coronary heart. Ann. N. Y. Acad. Sci. 1188, 39–45 (2010).
Mohan, M. L. & Naga Prasad, S. V. Scaffolding perform of PI3Kγ emerges from enzyme’s shadow. J. Mol. Biol. 429, 763–772 (2017).
Winter, G. E. et al. Phthalimide conjugation as a method for in vivo goal protein degradation. Science 348, 1376–1381 (2015).
Bai, L. et al. A potent and selective small-molecule degrader of STAT3 achieves full tumor regression in vivo. Most cancers Cell 36, 498–511 (2019).
Kaneshige, A. et al. A selective small-molecule STAT5 PROTAC degrader able to attaining tumor regression in vivo. Nat. Chem. Biol. 19, 703–711 (2023).
Koide, E. et al. Improvement and characterization of selective FAK inhibitors and PROTACs with in vivo exercise. Chembiochem 24, e202300141 (2023).
Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of quick DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
Ramirez, F. et al. deepTools2: a subsequent technology net server for deep-sequencing knowledge evaluation. Nucleic Acids Res. 44, W160–W165 (2016).
Pohl, A. & Beato, M. bwtool: a software for bigWig information. Bioinformatics 30, 1618–1619 (2014).
Martz, C. A. et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci. Sign. 7, ra121 (2014).
Su, A. et al. The folate cycle enzyme MTHFR is a important regulator of cell response to MYC-targeting therapies. Most cancers Discov. 10, 1894–1911 (2020).
Lin, Ok. H. et al. P2RY2–Akt activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. Nat. Most cancers 3, 837–851 (2022).
Brinkman, E. Ok., Chen, T., Amendola, M. & van Steensel, B. Straightforward quantitative evaluation of genome modifying by sequence hint decomposition. Nucleic Acids Res. 42, e168 (2014).
Kuo, Y. H. et al. Cbfβ-SMMHC induces distinct irregular myeloid progenitors in a position to develop acute myeloid leukemia. Most cancers Cell 9, 57–68 (2006).
Pimentel, H., Bray, N. L., Puente, S., Melsted, P. & Pachter, L. Differential evaluation of RNA-seq incorporating quantification uncertainty. Nat. Strategies 14, 687–690 (2017).
Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation evaluation for microarray and RNA-seq knowledge. BMC Bioinf. 14, 7 (2013).
Trott, O. & Olson, A. J. AutoDock Vina: enhancing the pace and accuracy of docking with a brand new scoring perform, environment friendly optimization, and multithreading. J. Comput. Chem. 31, 455–461 (2010).
